臨床薬理
Online ISSN : 1882-8272
Print ISSN : 0388-1601
ISSN-L : 0388-1601
特集/関節リウマチ治療における分子標的薬の進歩
2.IL-6 標的薬
西本 憲弘
著者情報
ジャーナル 認証あり

2013 年 44 巻 1 号 p. 9-14

詳細
抄録

Interleukin-6 (IL-6) is a multifunctional cytokine that regulates immune responses and inflammatory reactions. Deregulated over-production of IL-6 plays pathological roles in rheumatoid arthritis (RA). Therefore, blocking IL-6 actions can be a treatment for this disease. Tocilizumab is a humanized anti-human IL-6 receptor antibody and has just become available worldwide. Tocilizumab specifically blocks IL-6 binding to both membrane-bound and soluble forms of IL-6 receptor, and inhibits IL-6 signal transduction. Tocilizumab, both as monotherapy and in combination with methotrexate (MTX), has been shown to be effective in patients with RA refractory to MTX or other disease-modifying anti-rheumatic drugs. Tocilizumab also has therapeutic benefit in patients who are refractory to tumor necrosis factor inhibitors. Moreover, tocilizumab retards the progression of structural joint damage. The safety profile of tocilizumab is acceptable based on a large registry data. The agent is now approved in more than 100 countries. (Jpn J Clin Pharmacol Ther 2013; 44(1): 9-14)

著者関連情報
© 2013 日本臨床薬理学会
前の記事 次の記事
feedback
Top